Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics (ASX:PTX) is at the forefront of this approach with PTX-100, a small molecule which...
Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase...
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics Ltd (ASX:PTX) has highlighted continued progress across its oncology development pipeline during the...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.